Lee Ainslie's ABT Position Overview
Lee Ainslie (via Maverick Capital LTD) currently holds 1.76 M shares of Abbott Laboratories (ABT) worth $180.51 M, representing 2.08% of the portfolio. First purchased in 2019-Q3, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Lee Ainslie has maintained a strategic position in ABT, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 1.76 M shares. Largest reduction occurred in Q1 2020, reducing 92,575 shares.
Analysis based on 13F filings available since 2013 Q2
Lee Ainslie's Abbott Laboratories (ABT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Abbott Laboratories (ABT) Trades by Lee Ainslie
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +1.76 M | New Buy | 1.76 M | $102.67 |
| Q1 2024 | -24,977 | Sold Out | 0 | $0.00 |
| Q4 2023 | +194 | Add 0.78% | 24,977 | $110.07 |
| Q3 2023 | +24,783 | New Buy | 24,783 | $96.85 |
| Q2 2023 | -18,902 | Sold Out | 0 | $0.00 |
| Q1 2023 | +3,841 | Add 25.50% | 18,902 | $101.26 |
| Q4 2022 | +5,812 | Add 62.84% | 15,061 | $109.79 |
| Q3 2022 | +966 | Add 11.66% | 9,249 | $96.77 |
| Q2 2022 | -10,074 | Reduce 54.88% | 8,283 | $108.66 |
| Q1 2022 | +18,357 | New Buy | 18,357 | $118.37 |
| Q4 2021 | -43,854 | Sold Out | 0 | $0.00 |
| Q3 2021 | +10,756 | Add 32.50% | 43,854 | $118.12 |
| Q2 2021 | +9,263 | Add 38.86% | 33,098 | $115.93 |
| Q1 2021 | -37,908 | Reduce 61.40% | 23,835 | $119.82 |
| Q4 2020 | +41,106 | Add 199.19% | 61,743 | $109.49 |
| Q3 2020 | +2,004 | Add 10.76% | 20,637 | $108.83 |
| Q2 2020 | -11,129 | Reduce 37.39% | 18,633 | $91.45 |
| Q1 2020 | -92,575 | Reduce 75.67% | 29,762 | $78.93 |
| Q4 2019 | +60,003 | Add 96.26% | 122,337 | $86.86 |
| Q3 2019 | +62,334 | New Buy | 62,334 | $83.66 |
Lee Ainslie's Abbott Laboratories Investment FAQs
Lee Ainslie first purchased Abbott Laboratories (ABT) in Q3 2019, acquiring 62,334 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Lee Ainslie has held Abbott Laboratories (ABT) for 20 quarters since Q3 2019.
Lee Ainslie's largest addition to Abbott Laboratories (ABT) was in Q1 2026, adding 1,758,160 shares worth $180.51 M.
According to the latest 13F filing for Q1 2026, Lee Ainslie's firm, Maverick Capital LTD, owns 1,758,160 shares of Abbott Laboratories (ABT), valued at approximately $180.51 M.
As of the Q1 2026 filing, Abbott Laboratories (ABT) represents approximately 2.08% of Lee Ainslie's publicly disclosed stock portfolio, making it one of their key holdings.
Lee Ainslie's peak holding in Abbott Laboratories (ABT) was 1,758,160 shares, as reported at the end of Q1 2026.